Blood test may predict who benefits from targeted radiation therapy
NCT ID NCT06876532
First seen Nov 01, 2025
Summary
This study looks at whether an inflammation-based score (using CRP and albumin levels) can predict how well patients with advanced intestinal neuroendocrine tumors respond to Lu-177 oxodotreotide therapy. Researchers will follow 150 patients for 36 months, collecting blood samples and imaging data. The goal is to see if a simple, non-invasive test can help identify who is most likely to benefit from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTESTINAL NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Hôtel Dieu
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Bordeaux
NOT_YET_RECRUITINGBordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Lille
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Lyon
NOT_YET_RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Poitiers
NOT_YET_RECRUITINGPoitiers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centre François Baclesse
RECRUITINGCaen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital La Timone
NOT_YET_RECRUITINGMarseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
IUCT-O
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITINGAngers, 49055, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu-177 oxodotreotide (a radioactive drug given as standard treatment)
What this could lead to
If successful, this could give doctors a simple blood test to predict which patients will respond to Lu-177 therapy, helping personalize treatment decisions.
What could go wrong
This is an observational study, not a treatment trial. The inflammation score is experimental and may not prove accurate enough for routine use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.